{"id":4531,"date":"2025-03-31T18:12:11","date_gmt":"2025-03-31T18:12:11","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/indinavir-txt\/"},"modified":"2025-03-31T18:12:11","modified_gmt":"2025-03-31T18:12:11","slug":"indinavir-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/indinavir-txt\/","title":{"rendered":"indinavir.txt"},"content":{"rendered":"

indinavir <\/h1>\n

CLINICAL USE <\/H3>
\nProtease inhibitor:Treatment of HIV infection, in combination with a nucleoside reverse transcriptase inhibitor

DOSE IN NORMAL RENAL FUNCTION <\/H3>800 mg every 8 hours

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :711.9 (as sulphate)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :60<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 10.4<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :14<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :1.8\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function Monitor closely
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function Monitor closely
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function Monitor closely

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: possibly increased amiodarone concentration \u2013 avoid concomitant use\n
  • Antibacterials: rifampicin increases metabolism \u2013 avoid concomitant use; increased rifabutin concentration and rifabutin reduces indinavir concentration \u2013 reduce dose of rifabutin by 50% and increase dose of indinavir; avoid with telithromycin in severe renal and hepatic failure\n
  • Antidepressants: plasma concentration reduced by St John\u2019s wort \u2013 avoid concomitant use\n
  • Anti-epileptics: concentration possibly reduced by carbamazepine, phenytoin, primidone and barbiturates\n
  • Antifungals: ketoconazole inhibits metabolism \u2013 reduce dose of indinavir to 600 mg every 8 hours; concentration increased by itraconazole \u2013 consider reducing indinavir\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: possibly increased risk of ventricular arrhythmias with pimozide and sertindole \u2013 avoid concomitant use; possibly inhibits aripiprazole metabolism \u2013 reduce aripiprazole dose\n
  • Antivirals: avoid with atazanavir; concentration reduced by efavirenz and nevirapine; with nelfinavir and darunavir, concentration of both drugs increased; concentration increased by ritonavir; saquinavir concentration increasedAnxiolytics and hypnotics: increased risk of prolonged sedation with alprazolam and midazolam \u2013 avoid concomitant useCilostazol: concentration of cilostazol possibly increased \u2013 avoid concomitant use\n
  • Ergot alkaloids: risk of ergotism \u2013 avoid concomitant useLipid-regulating drugs: increased risk of myopathy with simvastatin \u2013 avoid concomitant use; and possibly with atorvastatin5HT 1 agonists: concentration of eletriptan increased \u2013 avoid concomitant useSildenafil: concentration of sildenafil increased \u2013 reduce initial sildenafil dose\n
  • Vardenafil: concentration of vardenafil increased \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>Drink 1.5 litres of water in 24 hours .380 indinAVirGive 1 hour before, or 2 hours after food, or with a low fat meal with water

    OTHER INFORMATION <\/H4>If giving with didanosine, leave 1 hour between each drugMild renal insufficiency is usually due to crystalluria, but a case of interstitial nephritis has been reportedIf nephrolithiasis with flank pain occurs (with or without haematuria), temporarily stop therapy (e.g. for 1\u20133 days)
    \n","protected":false},"excerpt":{"rendered":"

    indinavir CLINICAL USE Protease inhibitor:Treatment of HIV infection, in combination<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4531","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4531"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4531\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}